Former Lunesta marketing director leaves post

Share this article:
Tim Healey, the marketer at the helm during the hugely successful launch of sleep aid Lunesta, has left Sepracor to join Cambridge, MA, iron oxide nanoparticle firm Advanced Magnetics. Healey worked at Sepracor in various roles since 2001, most recently as executive director of CNS marketing. In 2005, Healey led the marketing charge behind the Lunesta launch. Facing stiff competition from Sanofi-Aventis’ Ambien, Lunesta achieved sales of approximately $465 million during its first year. As a result, Healey’s work was acknowledged with several industry awards. In January, the Lunesta marketing team was recognized as MM&M’s “Marketing Team of the Year.” The team also picked up a Gold Award at the 2005 MM&M Awards. In his new role, as SVP of commercial operations at Advanced Magnetics, Healey will be responsible for developing and implementing sales and marketing strategies for all of Advanced Magnetics’ products and product candidates. Those products include Feridex IV an agent for use with MRI for the detection of liver lesions; Ferumoxytol, a Phase III iron replacement therapeutic for chronic kidney disease patients and the investigational compound Combidex, a molecular imaging agent for use in conjunction with magnetic resonance imaging.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...